Levormeloxifene inhibits vaginal tropoelastin and transforming growth factor beta 1 production

Peter Takacs, Sujata Yavagal, Yanping Zhang, Keith Candiotti, Carlos A. Medina

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Purpose: To measure the effects of levormeloxifene on vaginal smooth muscle cell (SMC) proliferation, tropoelastin and transforming growth factor (TGF)-β1 production. Methods: Primary SMC cultures were performed from vaginal wall biopsies. SMC were incubated with levormeloxifene (0.1 μM, 1 μM), in 96-well plates and cell proliferation was assessed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoliumbromide (MTT) assay at 24 hours. Tropoelastin production was measured by the Fastin Assay kit and TGF-β1 levels were assessed by ELISA. Results: SMC proliferation was significantly increased by levormeloxifene [relative cell number, mean ± SE, levormeloxifene 0.1 μM 130 ± 13% of control (P=NS), 1 μM 151 ± 19% of control (P<0.05)]. Tropoelastin production was significantly decreased by levormeloxifene [mean β SE, levormeloxifene 0.1 μM 75 ± 4% of control (P=NS), 1 μM 64 ± 2% of control (P<0.05)]. In addition, TGF-β1 production was significantly decreased [mean ± SE, levormeloxifene 0.1 μM 79 ± 11% of control (P=NS), 1 μM 72 ± 14% of control (P<0.05)]. Conclusions: Levormeloxifene increases vaginal SMC proliferation, inhibits tropoelastin and TGF-β1 production.

Original languageEnglish (US)
Pages (from-to)11-19
Number of pages9
JournalJournal of Smooth Muscle Research
Issue number1
StatePublished - 2011


  • Elastin
  • Levormeloxifene
  • Smooth muscle
  • Transforming growth factor

ASJC Scopus subject areas

  • Physiology


Dive into the research topics of 'Levormeloxifene inhibits vaginal tropoelastin and transforming growth factor beta 1 production'. Together they form a unique fingerprint.

Cite this